PRC
HRTX icon

Pearl River Capital’s Heron Therapeutics HRTX Stock Holding History

Pearl River Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,000
Closed -$48K – 371
2019
Q1 		$48K Buy
2,000
+1,900
+1,900% +$49.7K 0.12% 237
2018
Q4 		$3K Buy
+100
New +$2.75K 0.01% 762

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Pearl River Capital's HRTX Position: Q2 2019 in Review

Pearl River Capital sold out of Heron Therapeutics (HRTX) in Q2 2019, closing a stake of 2,000 shares — an estimated $48K sold.

Pearl River Capital first reported a position in HRTX in Q4 2018 and held it in 2 quarters. The position peaked at $48K in Q1 2019. 176 funds tracked by Wall St. Rank hold HRTX as of Q2 2019.

  • Pearl River Capital reported no remaining Heron Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Pearl River Capital sold 2,000 Heron Therapeutics shares in Q2 2019, an estimated $48K.
  • Pearl River Capital first reported a position in Heron Therapeutics in Q4 2018 and held it in 2 quarters.
  • Pearl River Capital's Heron Therapeutics position peaked at $48K in Q1 2019.
  • 176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2019.

Based on Pearl River Capital's 13F filing for Q2 2019, filed 12 Aug 2019.